Cassava Sciences, Inc. Warrant
Limited financial coverage for SAVAW.
Not enough data to compute a meaningful composite — typical for foreign-listed ADRs, recent IPOs, or thinly-covered small caps. Live quote, chart, and any available stats still render below.
Price Chart
About the company
Cassava Sciences, Inc. is a biotechnology firm currently in the clinical development stage, dedicated to discovering therapies for neurodegenerative disorders. Their key therapeutic asset is simufilam, a small molecule drug that has already completed its Phase 2b clinical evaluation.
- CEO
- Richard Jon Barry
- IPO
- 2024
- Employees
- 30
- HQ
- Austin, TX, US
Get TickerSpark's AI analysis on SAVAW
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- 52W High
- $11.02
- 52W Low
- $0.02
- 50D MA
- $3.49
- 200D MA
- $4.93
- Beta
- -0.74
- RSI (14)
- 29
- Avg Volume
- 331.00K
No earnings-call transcripts are available for SAVAW yet.
- Free Float
- 97.9%
- Shares Outstanding
- 48.31M
- Float Shares
- 47.32M
Our SAVAW coverage
Recent articles, reports, and earnings notes.
No research on SAVAW yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SAVAW report →